Ultivue Develops Innovative Reagent-Based Solutions That Maximize The Biological Information Available From Cells And Tissue Samples

SSupported by cloud service provider DigitalOcean – Try DigitalOcean now and receive a $200 when you create a new account!
Listen to this article

Below is our recent interview with Kirsteen Maclean from Ultivue:

Q: Could you provide our readers with a brief introduction to your company?

A: We produce a sensitive, easy to use multiplex staining technology, InSituPlex®, that allows simultaneous visualization of multiple molecular species in tissue sections used for pathologic interpretation.

Recommended: Meet Super Hi-Fi – A Company That Provides Advanced Technology (AI) Services To Music Experience Providers

Q: Any highlights on your recent announcement?

A: We are thrilled to have Fenel Eloi and Mary Pat Lancelotta join our board, we’ve had a busy and exciting year at Ultivue. The combination of Mary Pat’s experience and ability in driving innovative scientific strategy for a global market, alongside Fenel’s familiarity enabling technology advancements within our partnership ecosystem, will further enable our customers bring exciting new therapies to market and positively impact the drive for personalized cancer treatment.

Q: Can you give us more insights into your offering?

A: InSituPlex® assays can be automated on standard robotic autostainers or applied manually in a workflow that mimics traditional immunohistochemistry. Furthermore, the InSituPlex nucleic acid hybridization-based signal amplification and detection means the tissue only needs to undergo mild antigen retrieval conditions during the staining and restaining process. This preserves tissue morphology and enables precise co-registration of multiplex images with the same H&E-stained tissue section used for pathologic diagnosis. These highly customizable solutions coupled to our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.

Q: What can we expect from your company in next 6 months? What are your plans?

A: Multiplex staining is primarily a research technique but if properly deployed will radically transform anatomic pathology practice and ultimately drug development and medical care.

Recommended: Vendita Delivers Database Automation And Compliance Tool That Helps Organizations With Their Digital Transformation

Q: What is the best thing about your company that people might not know about? Teamwork, inclusion and maintaining morale is so important in a world where many of us are working remotely.

A: Outside of a regular cadence of company communications, our culture team organizes monthly fun team building events, such as murder mysteries and trivia. It’s a great opportunity to catch up with your colleagues outside of the fast-paced work environment.